Dr. Morounfolu (Folu) Olugbosi joined TB Alliance on August 1, 2017, as Senior Director, Clinical Development and works with the clinical development of products in the TB Alliance portfolio, helps to oversee clinical trials in TB endemic countries and heads the South Africa office.
He obtained his medical degree at the College of Medicine, University of Lagos, Nigeria and specialized in Clinical Microbiology with primary interest in antimicrobial resistance during which he worked on Methicillin Resistant Staphylococcus aureus (MRSA) at the Otto von Guericke University, Magdeburg, Germany. He also obtained a Masters degree (cum laude) at the University of Siena, Italy in the field of Vaccinology and Pharmaceutical Clinical Development.
Between 2009 to 2017, he worked with Novartis Italy S.p.A as a Clinical Research Associate (CRA) and intern epidemiologist; Novartis South Africa (Pty) Ltd as Regional Physician, Middle East and Africa; Novartis USA Inc (transitioned to GSK) as Clinical Development Physician, North America and GSK South Africa (Pty) Ltd as Vaccines Medical Affairs Lead, South and Southern Africa. During this period, he worked on the clinical development of maternal immunization vaccines (Group B Streptococcus and Respiratory Syncytial Virus vaccines), meningococcal and Influenza vaccines; where he also co-authored numerous international peer reviewed publications.
His areas of experience also include medical affairs and pharmacovigilance.